Hangzhou Hansi Biological Pharmaceutical

Hangzhou Hansi Biological Pharmaceutical (Hansi Bio) is a clinical-stage biotechnology company headquartered in Hangzhou, China, dedicated to developing innovative antibody-based therapies for cancer. The company's lead asset, Pucocimab (HX008), is a humanized anti-PD-1 monoclonal antibody that has received marketing approval in China for the treatment of melanoma and MSI-H/dMMR solid tumors. Hansi Bio is also advancing HX009, a first-in-class bispecific antibody targeting both the PD-1 and VEGF pathways, which is currently in Phase 2 clinical trials. The company utilizes its proprietary antibody discovery and engineering platforms to build a robust pipeline of biologics aimed at addressing unmet medical needs in oncology. Founded by Dr. Guoliang Yu, Hansi Bio collaborates with international partners like Apollomics to expand the global reach of its therapeutic candidates. With a focus on high-affinity antibodies and combination strategies, the company is positioned as a significant player in the Chinese biopharmaceutical landscape.